<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731715</url>
  </required_header>
  <id_info>
    <org_study_id>YKP509C001</org_study_id>
    <nct_id>NCT03731715</nct_id>
  </id_info>
  <brief_title>Carisbamate in Adult &amp; Pediatric Subjects With Lennox-Gastaut Syndrome</brief_title>
  <official_title>Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Life Science, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with&#xD;
      LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a&#xD;
      Screening Period of up to 28 days and a Treatment Period of 87 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 24 subjects are planned: 6 subjects in each of 4 cohorts: Cohort I (≥18 years),&#xD;
      Cohort II (12 to &lt;18 years), Cohort III (6 to &lt;12 years), and Cohort IV (2 to &lt;6 years).&#xD;
&#xD;
      For Cohorts I and II, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma&#xD;
      concentrations, will be conducted on Days 1, 2 and 3 of the single dose period at pre-dose&#xD;
      and 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the&#xD;
      multiple-dose period at pre dose and 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours after dosing;&#xD;
      trough samples will be collected on Days 45 and 73 of the dose-adjustment period.&#xD;
&#xD;
      For Cohort III, PK assessments of carisbamate, S-enantiomer and its R-enantiomer plasma&#xD;
      concentrations will be conducted on Days 1, 2 and 3 of the single dose period at pre dose and&#xD;
      0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours after dosing and on Day 17 of the multiple-dose&#xD;
      period at pre-dose and 2 hours after dosing; trough samples will be collected on Days 45 and&#xD;
      73 of the dose-adjustment period.&#xD;
&#xD;
      For Cohort IV, a sparse PK sampling approach will be used, and the time of PK sampling time&#xD;
      will be based on the PK results from the other cohorts. A maximum of 2 to 4 time points on&#xD;
      each day (1 and 17) will be collected.&#xD;
&#xD;
      Safety assessments include adverse event (AE) and concomitant medication reporting, clinical&#xD;
      laboratory testing, vital sign measurements, 12 lead electrocardiograms (ECGs), physical&#xD;
      examinations, and neurologic examinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">June 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve (AUC) of carisbamate after a single and multiple doses of carisbamate.</measure>
    <time_frame>Days 1-3, Day 17</time_frame>
    <description>Safety Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) after a single and multiple doses of carisbamate.</measure>
    <time_frame>Days 1-3, Day 17</time_frame>
    <description>Safety assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - adverse events (AEs) reporting after a single and multiple doses of carisbamate.</measure>
    <time_frame>Days 1-87</time_frame>
    <description>Adverse event assessment for seriousness (yes, no), severity (mild, moderate, severe), affect on carisbamate dosing (increase, reduced, interrupted, withdrawn, no change), and outcome (recovered/resolved,recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal or unknown).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Lennox Gastaut Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ≥18 years of age. Carisbamate, 200 mg, will be administered on Day 1 and 2 of the single-dose period. Carisbamate will be administered at 100 mg twice daily (BID) during the multiple-dose period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 12 to &lt;18 years of age. Carisbamate, 140 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 70 mg twice daily (BID) during the multiple-dose period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 6 to &lt;12 years of age. Carisbamate, 60 mg, will be administered on Day 1 and 2 of the single dose period. Carisbamate will be administered at 30 mg twice daily (BID) during the multiple-dose period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 2 to &lt;6 years of age. The starting doses for the single dose and multiple-dose periods will be based on the PK and safety results of the first 3 cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carisbamate</intervention_name>
    <description>An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)</description>
    <arm_group_label>Cohort I</arm_group_label>
    <arm_group_label>Cohort II</arm_group_label>
    <arm_group_label>Cohort III</arm_group_label>
    <arm_group_label>Cohort IV</arm_group_label>
    <other_name>YKP509</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of LGS as evidenced by the following:&#xD;
&#xD;
               1. More than 1 type of generalized seizure, including drop seizures (atonic, tonic,&#xD;
                  or myoclonic), for ≥6 months before Visit 1&#xD;
&#xD;
               2. Previous electroencephalogram reporting diagnostic criteria for LGS (abnormal&#xD;
                  background activity accompanied by slow spike-and-wave pattern &lt;2.5 Hz)&#xD;
&#xD;
          2. Male or female aged ≥2 years at the time of consent&#xD;
&#xD;
          3. Aged &lt;11 years at the onset of LGS&#xD;
&#xD;
          4. Written informed consent signed by the subject or legal guardian prior to entering the&#xD;
             study in accordance with the ICH GCP guidelines. Age appropriate assent will be&#xD;
             obtained for children and adolescents. If the written informed consent is provided by&#xD;
             the legal guardian because the subject is unable to do so, a written or verbal assent&#xD;
             from the subject must also be obtained.&#xD;
&#xD;
          5. Receiving 1 to 3 concomitant AEDs at a stable dose for ≥30 days before Visit 1 (vagal&#xD;
             nerve stimulation [VNS] and ketogenic diet, stable and ongoing for ≥30 days before&#xD;
             Visit 1, do not count as AEDs)&#xD;
&#xD;
          6. In the Investigator's opinion, parents or caregivers must be able to report accurate&#xD;
             seizure assessments during the screening and study periods and subjects must be able&#xD;
             to ingest study drug&#xD;
&#xD;
          7. Body weight ≥8 kg for subjects enrolled in Cohort IV&#xD;
&#xD;
          8. Subjects with an implanted vagal nerve stimulator will be allowed if the vagal nerve&#xD;
             stimulator was implanted at least 5 months prior to Visit 1 (Screening) and the&#xD;
             stimulator parameters are not changed for 30 days prior to Visit 1 and for the&#xD;
             duration of the study&#xD;
&#xD;
          9. Subjects following a ketogenic diet will be allowed as long as the diet has been&#xD;
             stable for at least 30 days prior to Visit 1 (Screening) and will remain stable for&#xD;
             the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Progressive neurological disease&#xD;
&#xD;
          2. Prior treatment with carisbamate&#xD;
&#xD;
          3. Evidence of clinically significant disease or any medical condition that would&#xD;
             compromise the subject's ability to safely complete the study&#xD;
&#xD;
          4. Any surgical or medical condition that may interfere with the absorption,&#xD;
             distribution, metabolism, or excretion of the investigational medicine product&#xD;
&#xD;
          5. Acute disease state (e.g., nausea, vomiting, fever, or diarrhea) within 7 days before&#xD;
             Day 1&#xD;
&#xD;
          6. Scheduled for surgery during the study&#xD;
&#xD;
          7. Ketogenic diet or VNS, unless stable and ongoing for ≥30 days before Visit 1&#xD;
&#xD;
          8. Treatment with an investigational drug or device ≥30 days before Visit 1&#xD;
&#xD;
          9. Status epilepticus within 12 weeks of Visit 1&#xD;
&#xD;
         10. Felbamate for &lt;1 year (subjects taking felbamate for ≥1 year must have a stable dose&#xD;
             for 60 days before Visit 1)&#xD;
&#xD;
         11. Concomitant use of vigabatrin or other medications known to be inducers of CYP3A&#xD;
&#xD;
         12. Use of drugs known as UGT inducers, e.g., carbamazepine, phenytoin, phenobarbital,&#xD;
             primidone, or oxcarbazepine&#xD;
&#xD;
         13. Use of cannabinoids (any form), cannabidiols, or medical or recreational marijuana&#xD;
&#xD;
         14. Use of any prescription or non-prescription drugs, including over-the-counter&#xD;
             medication, non-routine vitamins and herbal products within 2 weeks prior to study&#xD;
             drug administration unless discussed and agreed with the Sponsor's medical&#xD;
             representative in writing. (Medication used to treat TEAEs does not lead to a&#xD;
             compulsory exclusion of subjects.)&#xD;
&#xD;
         15. Consumption of any caffeine-containing products (e.g., coffee, tea, chocolate, or&#xD;
             soda) or alcoholic beverages within 48 hours before Day 1 and until the end of each PK&#xD;
             sampling period&#xD;
&#xD;
         16. Consumption of grapefruit or grapefruit-containing products within 72 hours before Day&#xD;
             1 and until the end of each PK sampling period&#xD;
&#xD;
         17. History of any serious drug-induced hypersensitivity reaction (including but not&#xD;
             limited to Stevens Johnson syndrome, toxic epidermal necrolysis, Drug Rash with&#xD;
             Eosinophilia and Systemic Symptoms [DRESS]) or any drug-related rash requiring&#xD;
             hospitalization&#xD;
&#xD;
         18. History of AED-associated rash that involved conjunctiva or mucosae&#xD;
&#xD;
         19. History of more than one non-serious drug-related hypersensitivity reaction that&#xD;
             required discontinuation of the medication&#xD;
&#xD;
         20. Significant clinical laboratory abnormalities, including elevation of serum AST or ALT&#xD;
             more than 1.5 times ULN for age group, or any elevation of bilirubin or creatinine&#xD;
             about the ULN for age group at Screening&#xD;
&#xD;
         21. Any clinically-significant uncontrolled medical illness, including hepatic or renal&#xD;
             failure, ischemic disease, human immunodeficiency virus (HIV) infection, active&#xD;
             sexually-transmitted disease (STD), active viral hepatitis, malignancy, or any&#xD;
             disorder that in the judgement of the investigator places the subject at risk by&#xD;
             participation in this study&#xD;
&#xD;
         22. History of drug-induced liver injury&#xD;
&#xD;
         23. Positive urine screen of drugs of abuse (if not due to concomitant medication, e.g.&#xD;
             benzodiazepines as hypnotics) for adult and adolescent subjects.&#xD;
&#xD;
         24. Adrenocorticotropic hormone within the 6 months before Visit 1&#xD;
&#xD;
         25. History of anoxic episodes requiring resuscitation within 6 months before Visit 1,&#xD;
             drug or alcohol dependency or abuse within approximately the last 2 years, or use of&#xD;
             illegal recreational drugs&#xD;
&#xD;
         26. Females who are breastfeeding or pregnant at Screening or Baseline or who are of&#xD;
             reproductive age and do not agree to be abstinent or to use highly effective&#xD;
             contraception&#xD;
&#xD;
         27. Intermittent use of benzodiazepine of &gt;4 single administrations in the month before&#xD;
             Visit 1&#xD;
&#xD;
         28. Clinically significant abnormality on the 12-lead ECG at Screening, and any child or&#xD;
             adolescent with a QTcF less than 330 ms or greater than 450 ms&#xD;
&#xD;
         29. Congenital short QT syndrome&#xD;
&#xD;
         30. Hypersensitivity to the study drug or any of the excipients&#xD;
&#xD;
         31. Psychotic disorder(s) or unstable recurrent affective disorder(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ry R Forseth, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>SK Life Science, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marietta Atienza</last_name>
    <phone>201-614-2431</phone>
    <email>matienza@sklsi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Los Angeles - Pediatric Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Advent Health Tampa, Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Mid-Atlantic Epilepsy and Sleep Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra K Snogren</last_name>
      <phone>603-653-9948</phone>
      <email>sandra.k.snogren@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Richard P Morse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Lenox Hill</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke Health</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Willis, MD</last_name>
      <phone>610-425-7864</phone>
    </contact>
    <contact_backup>
      <email>nicole.a.willis@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Muhammad Zafar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryn McCarthy</last_name>
      <phone>503-418-8297</phone>
    </contact>
    <contact_backup>
      <email>mccarbry@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Colin Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Minnick</last_name>
      <phone>215-590-4136</phone>
      <email>minnick@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas Abend, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The University of Utah School of Medicine - Primary Children's Hospital (Primary Children's Medical Center)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Straley</last_name>
      <phone>801-213-9900</phone>
      <email>carly.straley@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Sweney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UW Valley Medical Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dione Froman</last_name>
      <phone>425-690-3503</phone>
      <email>dione_froman@valleymed.org</email>
    </contact>
    <investigator>
      <last_name>David Vossler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amber Hecker-Johnson</last_name>
      <phone>253-403-9348</phone>
    </contact>
    <contact_backup>
      <email>aheckerjohnson@multicare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lennox Gastaut Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

